Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, with a primary focus on recessive dystrophic epidermolysis bullosa (RDEB)ZEVASKYN® (prademagene zamikeracel), which Abeona describes as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
On this page, readers can follow ABEO news related to ZEVASKYN’s commercial rollout, including activation of new Qualified Treatment Centers, initial patient treatments, and updates on manufacturing and product release processes at the company’s cell and gene therapy cGMP facility in Cleveland, Ohio. Press releases also cover developments in reimbursement and market access, such as the assignment of a permanent HCPCS J-code (J3389) by the Centers for Medicare and Medicaid Services (CMS) and coverage decisions by commercial health plans.
Abeona’s news flow additionally features corporate and pipeline updates, including quarterly financial results, participation in investor conferences, and progress in its AAV-based gene therapy programs, such as the ABO-503 program for X-linked retinoschisis (XLRS) selected for the FDA’s Rare Disease Endpoint Advancement Pilot Program. Management appointments and employee equity inducement grants under Nasdaq Listing Rule 5635(c)(4) are also regular topics.
Investors, clinicians, and other stakeholders can use this ABEO news feed to review the company’s latest disclosures on commercial performance indicators, regulatory and payer milestones, treatment site expansion, and strategic pipeline initiatives in gene therapy.
Abeona Therapeutics (Nasdaq: ABEO) announced on December 31, 2025 that its Compensation Committee approved inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
On December 30, 2025 the committee granted restricted stock awards to seven new employees totaling up to 79,584 restricted shares. The awards vest in three equal annual instalments (one-third each year) and will be fully vested on the third anniversary of the grant date, subject to each employee’s continued employment.
Abeona Therapeutics (Nasdaq: ABEO) announced the appointment of Mohamad Tabrizi as Senior Vice President, Chief Business Officer effective Dec 15, 2025.
Mr. Tabrizi will lead corporate strategy and business development and drive operating efficiency. He joins from venture capital roles at Pandect Bioventures and Berkeley Catalyst Fund and held operational leadership at portfolio companies including Azkarra Therapeutics and Circle Pharma.
His background includes 20 transactions at Nektar Therapeutics and more than $5 billion raised in public and private financings while working in investment banking.
Abeona Therapeutics (Nasdaq: ABEO) announced on December 11, 2025 that The University of Texas Medical Branch (UTMB) in Galveston is now an activated Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets.
ZEVASKYN is an FDA-approved autologous gene therapy for adult and pediatric wounds caused by recessive dystrophic epidermolysis bullosa (RDEB). UTMB is described as a major academic center with expertise in complex skin disease and wound care. The announcement emphasizes expanded patient access across Texas and the Gulf Coast and points to Abeona Assist for patient support, insurance help, and logistical assistance.
Abeona Therapeutics (Nasdaq: ABEO) announced the first commercial patient treatment with FDA‑approved ZEVASKYN (prademagene zamikeracel) for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
The treatment was administered at Lucile Packard Children’s Hospital Stanford in Palo Alto, CA on Dec 8, 2025, and Abeona said additional patients are already scheduled for treatment in the new year. The company highlighted its Abeona Assist patient support program offering insurance benefit navigation, financial assistance, and travel/logistics help.
Abeona Therapeutics (Nasdaq: ABEO) announced on December 1, 2025 that its Compensation Committee approved inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to two newly hired non-executive employees.
On November 30, 2025 the committee granted restricted stock awards covering, in the aggregate, up to 45,685 restricted shares of Abeona common stock. The awards vest one-third on each anniversary of the grant date, so each grantee’s awards become fully vested on the third anniversary, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) reported Q3 2025 results and operational updates on Nov 12, 2025. Key points: ZEVASKYN patient treatment now anticipated to begin in 4Q 2025 after optimization of a rapid sterility release assay and resumed biopsy collection in November 2025. Early commercial momentum includes 12 ZEVASKYN product order forms received and ~30 eligible patients identified across treatment centers, with three activated Qualified Treatment Centers.
Financials: $207.5M in cash and equivalents as of Sept 30, 2025, expected to fund operations for >two years; Q3 R&D $4.2M vs $8.9M prior year; SG&A $19.3M vs $6.4M prior year; net loss $(5.2)M vs $(30.3)M prior year. CMS established permanent HCPCS J-code J3389 effective Jan 1, 2026.
Abeona Therapeutics (Nasdaq: ABEO) will report third quarter 2025 financial results and corporate progress on a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET. The call is available by phone (877-545-0523 U.S.; 973-528-0016 international) using Entry Code 922481, and via a live, listen-only webcast.
Management will also join a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 1:20 p.m. ET. Both webcasts will be archived on the company's Investors & Media events page for 30 days after each event.
Abeona Therapeutics (Nasdaq: ABEO) announced on November 3, 2025 that its Compensation Committee granted inducement restricted stock awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4).
On October 31, 2025, Abeona granted awards to eleven new hires covering up to 71,035 restricted shares of common stock. The awards vest one-third each year on the anniversary of the grant and are fully vested on the third anniversary, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) announced that the Centers for Medicare and Medicaid Services has established a permanent HCPCS J-code J3389 for ZEVASKYN (prademagene zamikeracel), its autologous gene‑modified cellular sheet for wounds in adult and pediatric recessive dystrophic epidermolysis bullosa (RDEB).
The J-code, defined as “Topical administration, prademagene zamikeracel, per treatment,” becomes effective January 1, 2026. Abeona said the product‑specific code will simplify claims and reimbursement, support hospital adoption, and improve patient access across public and private payers.
Abeona Therapeutics (Nasdaq: ABEO) appointed James A. Gow, MD, MBA, MS, MHCM as Senior Vice President, Head of Clinical Development & Medical Affairs, effective October 20, 2025.
Dr. Gow brings >20 years of industry experience in gene therapy and ophthalmology, having led programs from Phase 1 through post-marketing and contributed to FDA approvals for therapies including Xibrom, Bromday, Prolensa, Bepreve and global approvals for Xiidra. He previously held executive roles at Shire, Takeda, Novartis, Biogen and SparingVision and holds medical and multiple graduate degrees from the University of Manitoba, Cornell and Harvard.
FAQ
What is the current stock price of Abeona Therapeut (ABEO)?
What is the market cap of Abeona Therapeut (ABEO)?
